Identification of HDAC2 expression as a sensitive “epigenetic biomarker” associated with HDACis/DNA damaging agent's resistance may also lead to a new molecular target for CRC therapy and could help to improve treatment of the disease and provide a more robust mechanistic rationale for the use of HDACis. This evidence concerns the gene HDAC2 and colorectal carcinoma.